Amyris sees promising results for intranasal RNA/NLC vaccine

In California, Amyris, Inc. achieved promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI), which means an effective Covid-19 nose spray vaccine could become reality.

In-vivo results indicate that, when delivered to the mucosal membranes via intranasal administration, the Amyris/IDRI RNA vaccine generates antibodies and provides upper respiratory protection for SARS-CoV-2 (COVID-19), which Amyris believes has the potential to provide fuller protection against current variants of SARS-CoV-2. The Amyris/IDRI RNA technology may also support the potential for intranasal vaccine delivery that can protect against SARS-CoV-2 and other respiratory diseases, including the flu.

If approved and commercialized, the Amyris/IDRI RNA vaccine is targeted to be more accessible to people in underserved countries. In addition, the intranasal vaccine may offer improved upper respiratory protection beyond currently approved vaccines.